Calamos Advisors LLC grew its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 49.3% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 11,684 shares of the biopharmaceutical company’s stock after buying an additional 3,858 shares during the quarter. Calamos Advisors LLC’s holdings in Regeneron Pharmaceuticals were worth $5,738,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Korea Investment CORP raised its position in shares of Regeneron Pharmaceuticals by 223.9% during the 1st quarter. Korea Investment CORP now owns 298 shares of the biopharmaceutical company’s stock valued at $115,000 after buying an additional 206 shares in the last quarter. Sterling Investment Advisors Ltd. raised its position in Regeneron Pharmaceuticals by 11.2% in the 2nd quarter. Sterling Investment Advisors Ltd. now owns 278 shares of the biopharmaceutical company’s stock worth $137,000 after purchasing an additional 28 shares during the period. FNY Managed Accounts LLC purchased a new stake in Regeneron Pharmaceuticals in the 1st quarter worth about $140,000. Alpha Windward LLC raised its position in Regeneron Pharmaceuticals by 0.3% in the 2nd quarter. Alpha Windward LLC now owns 384 shares of the biopharmaceutical company’s stock worth $189,000 after purchasing an additional 1 shares during the period. Finally, IFP Advisors Inc raised its position in Regeneron Pharmaceuticals by 33.2% in the 2nd quarter. IFP Advisors Inc now owns 385 shares of the biopharmaceutical company’s stock worth $189,000 after purchasing an additional 96 shares during the period. Hedge funds and other institutional investors own 67.96% of the company’s stock.

REGN has been the topic of a number of recent analyst reports. Canaccord Genuity set a $484.00 price objective on shares of Regeneron Pharmaceuticals and gave the stock a “buy” rating in a research report on Tuesday, June 20th. Credit Suisse Group reissued a “buy” rating and issued a $485.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Monday, May 15th. BTIG Research reissued a “buy” rating and issued a $540.00 price objective (up from $480.00) on shares of Regeneron Pharmaceuticals in a research report on Friday, June 30th. BidaskClub lowered shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Thursday, July 6th. Finally, Bank of America Corporation reissued a “buy” rating and issued a $593.00 price objective (up from $589.00) on shares of Regeneron Pharmaceuticals in a research report on Friday, July 21st. Two analysts have rated the stock with a sell rating, thirteen have issued a hold rating, twelve have issued a buy rating and two have issued a strong buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus target price of $496.35.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) opened at 500.22 on Thursday. The firm has a 50 day moving average of $485.86 and a 200-day moving average of $442.34. The stock has a market cap of $53.04 billion, a PE ratio of 50.18 and a beta of 1.65. Regeneron Pharmaceuticals, Inc. has a 12-month low of $325.35 and a 12-month high of $543.55.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Thursday, August 3rd. The biopharmaceutical company reported $4.17 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $2.67 by $1.50. Regeneron Pharmaceuticals had a net margin of 22.05% and a return on equity of 25.58%. The business had revenue of $1.47 billion for the quarter, compared to analysts’ expectations of $1.36 billion. During the same period last year, the company earned $2.82 earnings per share. The company’s quarterly revenue was up 21.2% on a year-over-year basis. On average, analysts expect that Regeneron Pharmaceuticals, Inc. will post $14.85 earnings per share for the current year.

In related news, Director Joseph L. Goldstein sold 1,000 shares of the firm’s stock in a transaction that occurred on Friday, June 9th. The shares were sold at an average price of $482.55, for a total value of $482,550.00. Following the transaction, the director now owns 14,000 shares in the company, valued at $6,755,700. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CFO Robert E. Landry sold 189 shares of the firm’s stock in a transaction that occurred on Tuesday, September 5th. The shares were sold at an average price of $501.06, for a total transaction of $94,700.34. Following the completion of the transaction, the chief financial officer now owns 10,099 shares in the company, valued at approximately $5,060,204.94. The disclosure for this sale can be found here. Insiders sold 130,257 shares of company stock worth $62,227,944 over the last three months. Corporate insiders own 10.40% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Calamos Advisors LLC Acquires 3,858 Shares of Regeneron Pharmaceuticals, Inc. (REGN)” was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this article on another domain, it was stolen and reposted in violation of U.S. and international trademark and copyright laws. The correct version of this article can be viewed at https://www.thecerbatgem.com/2017/09/07/calamos-advisors-llc-acquires-3858-shares-of-regeneron-pharmaceuticals-inc-regn.html.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Stock Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.